Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies

Etienne Giroux Leprieur; David M. Jablons; Biao He

doi:10.18632/oncotarget.24411

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies

Etienne Giroux Leprieur _, David M. Jablons and Biao He

PDF | HTML | How to cite

Oncotarget. 2018; 9:14680-14691. https://doi.org/10.18632/oncotarget.24411

Metrics: PDF 1326 views | HTML 3161 views | ?

Abstract

Etienne Giroux Leprieur1,2, David M. Jablons3 and Biao He3

1Department of Respiratory Diseases and Thoracic Oncology, APHP - Ambroise Paré Hospital, Boulogne-Billancourt, France

2EA 4340 BCOH, UVSQ, Paris-Saclay University, Boulogne-Billancourt, France

3Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA

Correspondence to:

Etienne Giroux Leprieur, email: [email protected]

Keywords: Sonic Hedgehog; lung cancer; mesothelioma; cancer stem cell; chemoresistance

Received: November 11, 2017 Accepted: January 25, 2018 Epub: February 06, 2018 Published: March 06, 2018

ABSTRACT

The Sonic Hedgehog (Shh) pathway is physiologically involved during embryogenesis, but is also activated in several diseases, including solid cancers. Previous studies have demonstrated that the Shh pathway is involved in oncogenesis, tumor progression and chemoresistance in lung cancer and mesothelioma. The Shh pathway is also closely associated with epithelial-mesenchymal transition and cancer stem cells. Recent findings have revealed that a small proportion of lung cancer cells expressed an abnormal full-length Shh protein, associated with cancer stem cell features. In this paper, we review the role of the Shh pathway in thoracic cancers (small cell lung cancer, non-small cell lung cancer, and mesothelioma) and discuss the new perspectives of cancer research highlighted by the recent data of the literature.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24411

Publication Alerts

Reviews:

Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies

Abstract